Priyanka Tiwari
Share
Suspense crime, Digital Desk : New Delhi, India – India's drug regulator has given the green light to global pharmaceutical giant Eli Lilly to launch its blockbuster drug, Mounjaro, in the country. The approval marks the arrival of one of the world's most talked-about treatments for Type 2 diabetes, which has gained immense popularity for its remarkable weight-loss effects.
The Central Drugs Standard Control Organisation (CDSCO) has granted permission for the drug, with the generic name tirzepatide, to be marketed in India. Mounjaro is a once-a-week injectable medication that has shown outstanding results in both managing blood sugar levels and promoting significant weight loss in patients.
The approval specifically covers the launch of Mounjaro in a user-friendly, pre-filled pen format. This is a crucial detail for patients, as it means the drug will be easy to self-administer without the need for complicated mixing or measuring of doses.
The launch of Mounjaro is set to be a game-changer in the Indian healthcare market. It will directly compete with other popular drugs in the same class, like Novo Nordisk's Ozempic. Given the rising rates of obesity and diabetes in India, the demand for such effective treatments is expected to be massive.
While primarily approved for improving glycemic control in adults with Type 2 diabetes, Mounjaro's "off-label" use for weight management has fueled its global success. This approval by the CDSCO marks a significant milestone, providing doctors and patients in India with a powerful new option for managing these interconnected chronic conditions.
Read More: India and Russia Reaffirm Ties as Leaders Share Car Ride After Airport Greeting
